- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Lilly and SCRI team up to develop investigational oncology therapy
17 June 2015 • Author:
Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and programme design, as well as medical oversight and trial management. Patient enrolment for the initial Phase II clinical trial is underway.
“Lilly has a long history of leading innovation in cancer therapy with the goal to offer patients improved treatment outcomes,” said Christopher A. Slapak, M.D., vice president, early phase clinical research for Lilly. “This strategic partnership is an exciting step to foster further collaboration with SCRI in advancing the field of cancer research.”
SCRI’s large network of patients will help accelerate enrolment in the trial
The partnership supports the development of this novel targeted cancer therapy, including flexible and efficient programme design and implementation, as well as more rapid patient enrolment to clinical trials by accessing SCRI’s large network of patients.
“Our clinical trial management capabilities and scientific leadership, combined with Lilly’s leading drug development expertise, furthers our mission to advance therapies for patients seeking novel cancer medicines,” said Dee Anna Smith, CEO of SCRI. “Through partnerships like this one, we can accelerate the time it takes to bring clinical trials into communities for those fighting cancer.”
Focused on advancing therapies for patients, SCRI is one of the world’s leading clinical research organisations conducting community-based clinical trials in oncology, cardiology and orthopaedics. It has been a clinical trial leader in nearly 80% of approved cancer therapies in the last 10 years.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics